NPWA Stock Overview
Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Smith & Nephew plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£23.60 |
| 52 Week High | UK£28.40 |
| 52 Week Low | UK£22.00 |
| Beta | 0.70 |
| 11 Month Change | -10.61% |
| 3 Month Change | -14.49% |
| 1 Year Change | 0.85% |
| 33 Year Change | -16.31% |
| 5 Year Change | -40.10% |
| Change since IPO | 54.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| NPWA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 1.1% |
| 1Y | 0.9% | -5.7% | 7.2% |
Return vs Industry: NPWA exceeded the German Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: NPWA underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| NPWA volatility | |
|---|---|
| NPWA Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NPWA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NPWA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1856 | 18,000 | Deepak Nath | www.smith-nephew.com |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Smith & Nephew plc Fundamentals Summary
| NPWA fundamental statistics | |
|---|---|
| Market cap | €10.42b |
| Earnings (TTM) | €288.68m |
| Revenue (TTM) | €5.34b |
36.1x
P/E Ratio2.0x
P/S RatioIs NPWA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPWA income statement (TTM) | |
|---|---|
| Revenue | US$5.64b |
| Cost of Revenue | US$1.67b |
| Gross Profit | US$3.97b |
| Other Expenses | US$3.66b |
| Earnings | US$305.00m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 70.33% |
| Net Profit Margin | 5.41% |
| Debt/Equity Ratio | 66.7% |
How did NPWA perform over the long term?
See historical performance and comparison